M. Turk And İ. YILMAZ, "High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?," INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY , vol.182, no.5, pp.461-462, 2021
Turk, M. And YILMAZ, İ. 2021. High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY , vol.182, no.5 , 461-462.
Turk, M., & YILMAZ, İ., (2021). High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY , vol.182, no.5, 461-462.
Turk, MURAT, And İNSU YILMAZ. "High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?," INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY , vol.182, no.5, 461-462, 2021
Turk, MURAT And YILMAZ, İNSU. "High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?." INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY , vol.182, no.5, pp.461-462, 2021
Turk, M. And YILMAZ, İ. (2021) . "High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?." INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY , vol.182, no.5, pp.461-462.
@article{article, author={MURAT TÜRK And author={İNSU YILMAZ}, title={High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?}, journal={INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY}, year=2021, pages={461-462} }